Polyneuropathy occurs when multiple peripheral nerves become damaged. Symptoms include problems with sensation, coordination, or other body functions. Polyneuropathy is also known as peripheral ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects ...

Rockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 ...

Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and ...

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...

In the longest study of an RNAi therapeutic for any disease, patisiran treatment demonstrated modest improvements in patients with hereditary transthyretin-mediated amyloidosis with ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments - ...